尼龙1010/6及尼龙1010/66基本物理性能与组成的关系

尼龙1010/6 和尼龙1010/66 的基本物理性能随着组成的改变而改变,尼龙1010 含量高时,共聚物密度大于计算值;含量低时,共聚物密度小于计算值.尼龙1010 含量20%左右时,共聚物具有较大吸水率

Crystallization and melting behavior of nylon 66 poly(ether imide) blends

Isothermal crystallization and melting behavior of nylon 66 and its blends with poly(ether imide) (PEI) were investigated by differential scanning calorimetry. Crystallization kinetics such as overall rate constant Z and index n were calculated according to Avrami approach. Crystallization in the blend was retarded with respect to that of pure nylon 66 by incorporation of PEI with high glass transition temperature (T-g). The lowest growth rate of the spherulites was observed in the blends containing 10 and 15 wt% fraction of PEI. A transition temperature where positively birefringent spherulites disappear and negative birefringent spherulites develop was measured by thermal analysis. The transition temperature increased with content of PEI in the blends. A suitable range of isothermally crystallization temperatures, 238.5-246 degrees C, is suggested For determining the equilibrium melting points by means of Hoffman-Weeks approach.

Tremolite-reinforced nylon 66 composites: Mechanical and rheological properties

The reinforcement effect of an acicular inorganic filler, tremolite, on nylon 66 was studied. The mechanical properties of tremolite-filled nylon 66 composites and the effect of the filler particle size on them were obtained. The dynamic mechanical properties and rheological properties of the composites were measured. Two treatments, silane and unsaturated polyester, were used to improve the interface between tremolite and the nylon matrix. The morphologies of the composites were investigated using SEM. (C) 1998 John Wiley & Sons, Inc.

PA1010/66共聚物的松弛行为

研究了PA1010/66共聚物在液氮温度与Tm之间的松弛行为与组成的关系发现不同的松弛温度及损耗因子随共聚物组成的改变而变化的趋势不同随66含量增加，Tγ总趋势下降，Tβ总趋势增加，Tα先下降后增加；tanδ(γ)·tan-1δ(α)和tanδtan-1δ(α)先下降后增加，tanδ(α)先增大后减小。66占50％时，Tγ、Tβ极大，Tα最小；tanδ(γ)tanδ(β)、tanδ(β)·tan－1δ(α)最小，tanδ(α)最大.

辐射交联型PA－66机械物理性能研究

本文讨论了进口与国产ＰＡ—６６经钴源辐射交联后，对机械物理性能产生的影响。发现适量经辐射的ＰＡ—６６球压硬度、拉伸强度、Ｉｚｏｄ冲击强度都有较大幅度提高，并在１００，０００Ｇｙ剂量对达最大值，而断裂伸长率在１００，０００Ｇｙ剂量以下变化不大。国产ＰＡ—６６辐射后在乙二醇中，在２５０℃时，２小时不起层，性能变化不大，可替代进口材料。

MORPHOLOGY AND DYNAMIC-MECHANICAL PROPERTIES OF NYLON 66/POLY(ETHER IMIDE) BLENDS

The morphology and dynamic mechanical properties of blends of poly(ether imide) (PEI) and nylon 66 over the full composition range have been investigated. Torque changes during mixing were also measured. Lower torque values than those calculated by the log-additivity rule were obtained, resulting from the slip at the interface due to low interaction between the components. The particle size of the dispersed phase and morphology of the blends were examined by scanning electron microscopy. The composition of each phase was calculated. The blends of PEI and nylon 66 showed phase-separated structures with small spherical domains of 0.3 similar to 0.7 mu m. The glass transition temperatures (T(g)s) of the blends were shifted inward, compared with those of the homopolymers, which implied that the blends were partially miscible over a range of compositions. T-g1, corresponding to PEI-rich phase, was less affected by composition than T-g2, corresponding to nylon 66-rich phase. This indicated that the fraction of PEI mixed into nylon 66-rich phase increased with decreasing PEI content and that nylon 66 was rarely mixed into the PEI-rich phase. The effect of composition on the secondary relaxations was examined. Both T-beta, corresponding to the motion of amide groups in nylon 66, and T-gamma, corresponding to that of ether groups in PEI, were shifted to higher temperature, probably because of the formation of intermolecular interactions between the components.

硅灰石填充尼龙66的力学性能

硅灰石填充尼龙６６的力学性能王雪芹，李滨耀（中国科学院长春应用化学研究所长春１３００２２）关键词硅灰石，尼龙６６，填充改性，力学性能硅灰石是一种工业矿物，具有完整的短纤维针状结构，在塑料的填充改性中，能够与石棉、滑石、云母等相媲美，在欧美占无机填料市...

C 185 INST-D 2013. 366 Muestras de carpetas tejidas con hilos de algodón y la técnica del crochet y bordados con hilo seda (Casanare)

20 fotografías a color.

Descriptions and validation of the names of some high-rank syntaxa in the European Asplenietea trichomanis and Polypodietea

The paper presents the description of one new order (Asplenietalia septentrionalo-cuneifolii) and two new alliances (Arenarion bertolonii and Physoplexido comosae- Saxifragion petraeae). In addition, the syntaxon Asplenietalia lanceolato-obovati is here formally raised to the order level and the name Hypno-Polypodietalia vulgaris is validated.

SGK1 activity in Na+ absorbing airway epithelial cells monitored by assaying NDRG1-Thr(346/356/366) phosphorylation

Studies of HeLa cells and serum- and glucocorticoid-regulated kinase 1 (SGK1) knockout mice identified threonine residues in the n-myc downstream-regulated gene 1 protein (NDRG1-Thr(346/356/366)) that are phosphorylated by SGK1 but not by related kinases (Murray et al., Biochem J 385:1-12, 2005). We have, therefore, monitored the phosphorylation of NDRG1-Thr(346/356/366) in order to explore the changes in SGK1 activity associated with the induction and regulation of the glucocorticoid-dependent Na+ conductance (G (Na)) in human airway epithelial cells. Transient expression of active (SGK1-S422D) and inactive (SGK1-K127A) SGK1 mutants confirmed that activating SGK1 stimulates NDRG1-Thr(346/356/366) phosphorylation. Although G (Na) is negligible in hormone-deprived cells, these cells displayed basal SGK1 activity that was sensitive to LY294002, an inhibitor of 3-phosphatidylinositol phosphate kinase (PI3K). Dexamethasone (0.2 mu M) acutely activated SGK1 and the peak of this response (2-3 h) coincided with the induction of G (Na), and both responses were PI3K-dependent. While these data suggest that SGK1 might mediate the rise in G (Na), transient expression of the inactive SGK1-K127A mutant did not affect the hormonal induction of G (Na) but did suppress the activation of SGK1. Dexamethasone-treated cells grown on permeable supports formed confluent epithelial sheets that generated short circuit current due to electrogenic Na+ absorption. Forskolin and insulin both stimulated this current and the response to insulin, but not forskolin, was LY294002-sensitive and associated with the activation of SGK1. While these data suggest that SGK1 is involved in the control of G (Na), its role may be minor, which could explain why sgk1 knockout has different effects upon different tissues.

Unesp Ciência, 2015, ano 6, número 66

Revista elaborada pela Assessoria de Comunicação e Imprensa da Reitoria da UNESP

Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.